Pharmaceutical
The Weight-Loss Drug Boom: Novo Nordisk's โฌ432 Million Athlone Expansion
Novo Nordisk commits โฌ432 million to upgrade its Athlone facility, expanding manufacturing capacity for oral GLP-1 weight-loss and diabetes treatments.
15 Jun 2026